$2.1 0%
Price vs. AI Score (Last 150 days)
Data gathered: December 10

Data Bits

Data Bits Value / Change Benchmark
Job Posts 6 -14.3%
Sentiment 83 -3.5%
Webpage traffic 13,000 5%
Employee Rating 53 0%
Google Adspend $ N/A N/A
Google Trends -100%
Linkedin Employees 377 N/A
Lobbying Cost $7,000 0% N/A
Patents 2 0%
4chan Mentions 0%
Stocktwits Mentions 7 -22.2%
Stocktwits Subscribers 68,481 -0%
Twitter Followers 11,570 N/A
News Mentions 0%
Reddit Mentions 0%
Business outlook 31 0%

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

In the news

About Cronos Group

Cronos Group is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development.

Cronos Group
Price $2.1
Target Price Sign up
Market Cap $801M
Dividend Yield 0
Industry Medical Cannabis

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda
Q3 '2367M31M4M-1.6M-20M
Q2 '2342M27M3.1M-8.4M-19M
Q1 '2346M26M2.4M-19M-20M
Q4 '2255M29M-230,000-79M-28M
Q3 '2248M31M3.1M-37M-29M

Insider Transactions

ADLER JASON MARC filed to buy 1,402,304 shares at $1.7.
June 1 '23
ADLER JASON MARC filed to buy 1,376,054 shares at $1.8.
May 30 '23
ADLER JASON MARC filed to buy 1,306,055 shares at $1.9.
May 25 '23
ADLER JASON MARC filed to buy 1,236,056 shares at $1.9.
May 23 '23
ADLER JASON MARC filed to buy 1,166,056 shares at $1.8.
May 22 '23
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2023 AltIndex. All rights reserved.